Vasculitis and Giant Cell Arteritis

Top Story

Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents With Biologic Therapy

Healio Rheumatology, April 2018
Editorial

Giant Cell Arteritis: A Call for Interprofessional Education and Collaboration

Healio Rheumatology, April 2018
Leonard H. Calabrese, DO
As rheumatologists, we relish new cases of giant cell arteritis in their classic form. We have the capacity to make a bedside diagnosis with considerable diagnostic…
FDA News

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

April 6, 2018
The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab…
Feature

Diagnosis Detective: Deciphering dermatologic symptoms of rheumatic diseases

March 23, 2018
Many rheumatic diseases – including systemic lupus erythematous, scleroderma and the various forms of psoriasis – present with a multitude of dermatologic…
More Headlines »
CME

Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents with Biologic Therapy

This activity is supported by an educational grant from Genentech, Inc.

Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients…
More »
Video
Meeting News

VIDEO: Wechsler talks about role of biologics in eosinophilic granulomatosis with polyangiitis

April 10, 2017
More »
Resource Centers
American College of Rheumatology Annual Meeting

American College of Rheumatology Annual Meeting

CME

Rheumatic Immune-related Adverse Events: Multidisciplinary Perspectives on Recognition and Management

This activity is supported by an educational grant from Bristol-Myers Squibb.

The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new…
More »